Multiple Sclerosis

Home/Disease Specific/Multiple Sclerosis

Stem cells as the road to repairing Multiple Sclerosis

A clinical trial set to begin this month in Ottawa will test the safety and efficacy of mesenchymal stem cells to stimulate repair of damaged nerves in MS patients. This article was published simultaneously on Signals Blog. June3, 2015 By Lisa Willemse On any given day at the general campus of The Ottawa Hospital, you’re

Regenerative Medicine Study Underscores Lung Regeneration Capacity

April 28, 2015, Reid D'Amoco In diseases like cystic fibrosis, the lungs undergo constant healing and remodeling due to chronic infections. To better understand the repair mechanisms the lungs go through in diseases like CF and COPD, scientists have paid great attention to studying cellular regeneration. Scientists at the University of Pennsylvania and Duke University have discovered

Gladstone Scientists Discover Potential New Treatment for Multiple Sclerosis

Finding could have implications for other autoimmune disorders, such as type I diabetes SAN FRANCISCO, CA—APRIL 27, 2015—Scientists from the Gladstone Institutes have discovered a way to prevent the development of multiple sclerosis (MS) in mice. Using a drug that blocks the production of a certain type of immune cell linked to inflammation and autoimmunity, the

Drugs Lessen Multiple Sclerosis Damage in Mice

April 27, 2015 At a Glance In a mouse study, 2 drugs already on the market activated stem cells and repaired the type of brain damage seen in multiple sclerosis (MS). More research will be needed to determine whether the drugs could lead to novel MS therapies. MS is a disease in which a nerve-insulating

Drugs that activate brain stem cells may reverse multiple sclerosis

March 20, 2015 NIH-funded study identifies over-the-counter compounds that may replace damaged cells Two drugs already on the market — an antifungal and a steroid — may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in

Have researchers discovered the sound of the stars?

Posted: Mar 23, 2015 (Nanowerk News) Researchers from the University of Copenhagen are the first in the world to develop a secure way of measuring the important protein apo-M. This could prove relevant for research into diseases such as diabetes, arteriosclerosis and sclerosis. For the first time, researchers from the University of Copenhagen have managed

Does Amyloid Kill in Alzheimer’s, Heal in MS?

Fri, 03/13/2015 - 10:30am Cynthia Fox, Science Writer, Bioscience Technology Amyloid beta-peptideTwo groups have recently made strides with amyloid beta (aβ), the supposed main villain in Alzheimer’s disease. But while one group is tackling Alzheimer’s by reducing aβ, the other is tackling multiple sclerosis (MS) by using aβ.“It’s all fascinating,” Stanford University neurologist Lawrence Steinman told Bioscience


March 6, 2015 Houston, by Sarah Stubbs MS patient turned down for four clinical trials sees remarkable improvement after stem cell therapy - As Multiple Sclerosis Awareness Month kicks off this week, one Texas woman is sharing her remarkable story after receiving stem cell therapy through a proprietary technology developed by Houston-based Celltex Therapeutics Corporation

New target identified in fight against Alzheimer’s, multiple sclerosis

February 27, 2015 By Michael C. Purdy YAMING WANG/BERND ZINSELMEYER Normally, brain cells known as microglia (green) surround Alzheimer’s plaques (blue) to help clear such plaques and other cellular debris from the brain. But the microglia shown above lack a key protein involved in this process. Scientists think the protein may be a treatment target

More Promising Data on Stem Cell Transplant for MS

February 13, 2015 by Megan Brooks [Medscape Medical News] Autologous hematopoietic stem cell transplant (AHSCT) proved "unequivocally" superior to mitoxantrone in reducing imaging evidence of disease activity in patients with multiple sclerosis (MS) refractory to conventional therapy in a phase 2 randomized controlled trial. Over 4 years, patients who received AHSCT experienced 79% fewer new T2 lesions compared